76.7% complete cytogenetic response rate achieved in patients who failed second-generation TKI first-line therapy Molecular responses continue to deepen with extended treatment duration, reaching 60% ...
Sprycel, Tasigna, and Gleevec battle for supremacy in CML treatment. FDA accepted an sNDA for Bristol-Myers Squibb (BMS) and Otsuka Pharmaceutical’s chronic myeloid leukemia (CML) drug, Sprycel®, and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results